Harbor Investment Advisory LLC Sells 795 Shares of Moderna, Inc. (NASDAQ:MRNA)

Harbor Investment Advisory LLC lessened its holdings in Moderna, Inc. (NASDAQ:MRNA) by 10.6% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 6,718 shares of the company’s stock after selling 795 shares during the period. Harbor Investment Advisory LLC’s holdings in Moderna were worth $716,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of MRNA. LPL Financial LLC grew its position in Moderna by 7.2% in the third quarter. LPL Financial LLC now owns 115,782 shares of the company’s stock valued at $11,959,000 after acquiring an additional 7,811 shares during the last quarter. Mariner LLC grew its holdings in shares of Moderna by 5.2% during the third quarter. Mariner LLC now owns 20,242 shares of the company’s stock worth $2,091,000 after purchasing an additional 996 shares during the last quarter. Stifel Financial Corp grew its holdings in shares of Moderna by 19.0% during the third quarter. Stifel Financial Corp now owns 75,871 shares of the company’s stock worth $7,837,000 after purchasing an additional 12,099 shares during the last quarter. Northern Trust Corp grew its holdings in shares of Moderna by 1.9% during the third quarter. Northern Trust Corp now owns 2,971,056 shares of the company’s stock worth $306,880,000 after purchasing an additional 55,177 shares during the last quarter. Finally, Meiji Yasuda Asset Management Co Ltd. grew its holdings in shares of Moderna by 12.2% during the third quarter. Meiji Yasuda Asset Management Co Ltd. now owns 3,610 shares of the company’s stock worth $373,000 after purchasing an additional 393 shares during the last quarter. Institutional investors own 75.33% of the company’s stock.

Analysts Set New Price Targets

MRNA has been the topic of several research reports. HSBC restated a “reduce” rating and set a $86.00 price target (up from $75.00) on shares of Moderna in a report on Monday, February 26th. Jefferies Financial Group restated a “buy” rating and set a $125.00 price target on shares of Moderna in a report on Tuesday, April 9th. Canaccord Genuity Group upped their target price on Moderna from $91.00 to $106.00 and gave the company a “hold” rating in a report on Friday, May 3rd. Evercore ISI began coverage on Moderna in a report on Tuesday, May 14th. They issued an “in-line” rating and a $120.00 target price on the stock. Finally, UBS Group upped their target price on Moderna from $143.00 to $151.00 and gave the company a “buy” rating in a report on Tuesday, May 7th. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and six have given a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $129.02.

Moderna Price Performance

Shares of MRNA opened at $137.00 on Tuesday. Moderna, Inc. has a 52-week low of $62.55 and a 52-week high of $170.47. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.91 and a current ratio of 4.03. The business’s 50 day moving average price is $132.34 and its two-hundred day moving average price is $110.92. The firm has a market cap of $52.50 billion, a PE ratio of -8.74 and a beta of 1.54.

Moderna (NASDAQ:MRNA) last issued its earnings results on Thursday, May 2nd. The company reported ($3.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($3.59) by $0.52. Moderna had a negative return on equity of 20.10% and a negative net margin of 115.82%. The company had revenue of $167.00 million for the quarter, compared to analyst estimates of $93.26 million. During the same period in the prior year, the firm earned $0.19 earnings per share. Moderna’s revenue for the quarter was down 91.0% on a year-over-year basis. On average, equities analysts anticipate that Moderna, Inc. will post -7.5 EPS for the current year.

Insider Transactions at Moderna

In related news, Director Noubar Afeyan sold 15,000 shares of the stock in a transaction on Wednesday, April 3rd. The stock was sold at an average price of $101.68, for a total value of $1,525,200.00. Following the completion of the sale, the director now directly owns 2,086,931 shares of the company’s stock, valued at approximately $212,199,144.08. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In related news, Director Noubar Afeyan sold 15,000 shares of the stock in a transaction on Wednesday, April 3rd. The stock was sold at an average price of $101.68, for a total value of $1,525,200.00. Following the completion of the sale, the director now directly owns 2,086,931 shares of the company’s stock, valued at approximately $212,199,144.08. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Shannon Thyme Klinger sold 5,178 shares of the stock in a transaction on Monday, June 10th. The shares were sold at an average price of $148.09, for a total value of $766,810.02. Following the completion of the sale, the insider now directly owns 15,947 shares of the company’s stock, valued at $2,361,591.23. The disclosure for this sale can be found here. Insiders have sold 411,255 shares of company stock valued at $55,846,531 over the last ninety days. 15.20% of the stock is owned by company insiders.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.